Clinical trial
Biodistribution Study of CMD-193 in Patients With Advanced Tumours Expressing…
NCT00293215 · Ludwig Institute for Cancer Research, Other · Terminated
Key facts
| NCT number | NCT00293215 |
|---|---|
| Title | Biodistribution Study of CMD-193 in Patients With Advanced Tumours Expressing the Lewis-Y Antigen |
| Official title | Phase I Biodistribution Study of 111-Indium-CMD-193 in Patients With Advanced Tumours Expressing the Lewis-Y Antigen |
| Lead sponsor | Ludwig Institute for Cancer Research, Other |
| Collaborators | Wyeth is now a wholly owned subsidiary of Pfizer Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Neoplasms |
| Intervention type | Drug |
| Interventions | 111-Indium-CMD-193, CMD-193 |
| Enrollment | 9 |
| Start date | Feb 1, 2006 |
| Primary completion | May 1, 2007 |
| Completion | May 1, 2007 |
| First posted | Feb 17, 2006 |
| Last update posted | Oct 10, 2022 |
| Countries | Australia |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: